Axitinib (Inlyta – Pfizer), an oral tyrosine kinase inhibitor, has been approved by the FDA for treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. It is the fourth oral tyrosine kinase inhibitor to be approved for treatment of advanced renal cell carcinoma.1,2

STANDARD TREATMENT — Surgery is the preferred treatment for resectable renal cell cancer. Agents that prevent tumor angiogenesis and proliferation through inhibition of vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathways have now become the standard of care for unresectable or metastatic disease.3

Sunitinib is the most widely used tyrosine kinase inhibitor for initial treatment of advanced renal carcinoma, but no direct comparisons with other tyrosine kinase inhibitors are available. Everolimus ... more      

Would you like to read the rest of this article?  Gain access below.